Amgen’s FTC Settlement To Allow $27.8bn Horizon Deal Closure Sets New M&A Precedent

Transaction Expected To Conclude Early In Q4

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Amgen agreed not to include Horizon’s Tepezza and Krystexxa in rebate bundling deals with payers, among other terms, so the FTC would clear the companies’ merger, giving pharma firms a new consideration in future dealmaking.

Amgen headquarters in Thousand Oaks
Amgen expects to close its Horizon purchase in the near term • Source: Shutterstock

Amgen, Inc. entered into a nationwide settlement with the US Federal Trade Commission and six states that sought to block the company’s $27.8bn acquisition of Horizon Therapeutics plc, clearing the way for the two entities to close their transaction early in the fourth quarter of this year and giving big pharma buyers a new set of considerations to address when assessing potentials mergers and acquisitions.

The settlement announced on 1 September addresses the FTC’s concerns – first raised in a lawsuit the regulator filed in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.